ES2687415T3 - Nuevas secuencias señal para mejorar las expresiones de proteínas y la secreción de enzimas recombinantes y de otras proteínas - Google Patents
Nuevas secuencias señal para mejorar las expresiones de proteínas y la secreción de enzimas recombinantes y de otras proteínas Download PDFInfo
- Publication number
- ES2687415T3 ES2687415T3 ES11843849.8T ES11843849T ES2687415T3 ES 2687415 T3 ES2687415 T3 ES 2687415T3 ES 11843849 T ES11843849 T ES 11843849T ES 2687415 T3 ES2687415 T3 ES 2687415T3
- Authority
- ES
- Spain
- Prior art keywords
- sequence
- seq
- dna
- bip
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010076504 Protein Sorting Signals Proteins 0.000 title claims abstract description 129
- 108090000623 proteins and genes Proteins 0.000 title claims description 84
- 102000004169 proteins and genes Human genes 0.000 title claims description 80
- 102000004190 Enzymes Human genes 0.000 title claims description 17
- 108090000790 Enzymes Proteins 0.000 title claims description 17
- 230000014509 gene expression Effects 0.000 title description 83
- 230000028327 secretion Effects 0.000 title description 33
- 239000012634 fragment Substances 0.000 claims abstract description 42
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 28
- 101000899240 Homo sapiens Endoplasmic reticulum chaperone BiP Proteins 0.000 claims abstract description 23
- 108020004414 DNA Proteins 0.000 claims description 62
- 229920001184 polypeptide Polymers 0.000 claims description 46
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 46
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 28
- 239000002253 acid Substances 0.000 claims description 27
- 108020001507 fusion proteins Proteins 0.000 claims description 26
- 102000037865 fusion proteins Human genes 0.000 claims description 26
- 230000002608 insulinlike Effects 0.000 claims description 25
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 14
- 102000014150 Interferons Human genes 0.000 claims description 14
- 108010050904 Interferons Proteins 0.000 claims description 14
- 102100038803 Somatotropin Human genes 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 13
- 108010076181 Proinsulin Proteins 0.000 claims description 13
- 108050007673 Somatotropin Proteins 0.000 claims description 13
- 239000013604 expression vector Substances 0.000 claims description 13
- 229940079322 interferon Drugs 0.000 claims description 13
- 102100036717 Growth hormone variant Human genes 0.000 claims description 12
- 101710191157 Growth hormone variant Proteins 0.000 claims description 12
- 239000000367 immunologic factor Substances 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 108700012359 toxins Proteins 0.000 claims description 3
- 108010017544 Glucosylceramidase Proteins 0.000 claims description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 2
- 102000004547 Glucosylceramidase Human genes 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 59
- 238000004113 cell culture Methods 0.000 description 54
- 241000282414 Homo sapiens Species 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 33
- 230000000694 effects Effects 0.000 description 31
- 239000013615 primer Substances 0.000 description 31
- 235000015097 nutrients Nutrition 0.000 description 21
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 16
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 15
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 15
- 229940068935 insulin-like growth factor 2 Drugs 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 230000002209 hydrophobic effect Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 108091008146 restriction endonucleases Proteins 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000006180 TBST buffer Substances 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000014616 translation Effects 0.000 description 9
- 108010087967 type I signal peptidase Proteins 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000002255 enzymatic effect Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 238000001243 protein synthesis Methods 0.000 description 7
- 230000007398 protein translocation Effects 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 239000006143 cell culture medium Substances 0.000 description 6
- 239000003636 conditioned culture medium Substances 0.000 description 6
- 210000000805 cytoplasm Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 101710194180 Alcohol oxidase 1 Proteins 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 108010051611 Signal Recognition Particle Proteins 0.000 description 5
- 102000013598 Signal recognition particle Human genes 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 238000003146 transient transfection Methods 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000010474 transient expression Effects 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000005431 Molecular Chaperones Human genes 0.000 description 3
- 108010006519 Molecular Chaperones Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000631463 Saara Species 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000001143 conditioned effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 101000616112 Homo sapiens Stress-associated endoplasmic reticulum protein 1 Proteins 0.000 description 2
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 101100476756 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) sec-61 gene Proteins 0.000 description 2
- 101150083515 RPL17 gene Proteins 0.000 description 2
- 102000002278 Ribosomal Proteins Human genes 0.000 description 2
- 108010000605 Ribosomal Proteins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100021813 Stress-associated endoplasmic reticulum protein 1 Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102100036790 Tubulin beta-3 chain Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000029054 response to nutrient Effects 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- -1 therapeutic antibody Proteins 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010056891 Calnexin Proteins 0.000 description 1
- 102100021868 Calnexin Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010089072 Dolichyl-diphosphooligosaccharide-protein glycotransferase Proteins 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101001040734 Homo sapiens Golgi phosphoprotein 3 Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 description 1
- 206010053317 Hydrophobia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 101000913652 Mus musculus Fibronectin type III domain-containing protein 5 Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710138718 Protochlorophyllide reductase B, chloroplastic Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 102000018673 SEC Translocation Channels Human genes 0.000 description 1
- 108010091732 SEC Translocation Channels Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000045921 human GAA Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 108010045758 lysosomal proteins Proteins 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 230000000858 peroxisomal effect Effects 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 108010000633 signal peptide receptor Proteins 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US415926P | 2002-10-03 | ||
| US41592610P | 2010-11-22 | 2010-11-22 | |
| PCT/US2011/061862 WO2012071422A2 (en) | 2010-11-22 | 2011-11-22 | Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2687415T3 true ES2687415T3 (es) | 2018-10-25 |
Family
ID=46146394
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11843849.8T Active ES2687415T3 (es) | 2010-11-22 | 2011-11-22 | Nuevas secuencias señal para mejorar las expresiones de proteínas y la secreción de enzimas recombinantes y de otras proteínas |
| ES18181451T Active ES2829199T3 (es) | 2010-11-22 | 2011-11-22 | Nuevas secuencias de señalización para mejorar la expresión y segregación de proteínas de enzimas recombinantes y otras proteínas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18181451T Active ES2829199T3 (es) | 2010-11-22 | 2011-11-22 | Nuevas secuencias de señalización para mejorar la expresión y segregación de proteínas de enzimas recombinantes y otras proteínas |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9279007B2 (enExample) |
| EP (2) | EP2643468B1 (enExample) |
| JP (1) | JP2014503198A (enExample) |
| KR (2) | KR20190060888A (enExample) |
| CN (1) | CN103328649B (enExample) |
| BR (1) | BR112013012671B1 (enExample) |
| CA (1) | CA2818689C (enExample) |
| CY (1) | CY1121049T1 (enExample) |
| DK (2) | DK2643468T3 (enExample) |
| ES (2) | ES2687415T3 (enExample) |
| HR (1) | HRP20181315T1 (enExample) |
| HU (1) | HUE039070T2 (enExample) |
| LT (1) | LT2643468T (enExample) |
| PL (1) | PL2643468T3 (enExample) |
| PT (1) | PT2643468T (enExample) |
| RS (1) | RS57601B1 (enExample) |
| SI (1) | SI2643468T1 (enExample) |
| SM (1) | SMT201800466T1 (enExample) |
| WO (1) | WO2012071422A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20192243T1 (hr) * | 2014-07-03 | 2020-03-06 | F. Hoffmann - La Roche Ag | Polipeptidni ekspresijski sustavi |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| EP3635009A1 (en) | 2017-06-07 | 2020-04-15 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| TW201927825A (zh) * | 2017-11-30 | 2019-07-16 | 美商阿米庫斯醫療股份有限公司 | Cdkl5 表現變體和cdkl5 融合蛋白 |
| SG11202007363TA (en) | 2018-02-07 | 2020-08-28 | Regeneron Pharma | Methods and compositions for therapeutic protein delivery |
| KR20210005154A (ko) | 2018-04-30 | 2021-01-13 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 유전자 요법 작제물 및 사용 방법 |
| CA3100021A1 (en) | 2018-05-17 | 2019-11-21 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| BR112021006829A2 (pt) | 2018-10-10 | 2021-07-20 | Amicus Therapeutics, Inc. | composições de polipeptídeos estabilizados com ligações dissulfeto e métodos de uso |
| EP3870600A1 (en) | 2018-10-24 | 2021-09-01 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| CA3120638A1 (en) * | 2018-12-19 | 2020-06-25 | Versameb Ag | Rna encoding a protein and a signal peptide with a hydrophobic amino-terminal end |
| CA3132840A1 (en) | 2019-03-08 | 2020-09-17 | Obsidian Therapeutics, Inc. | Human carbonic anhydrase 2 compositions and methods for tunable regulation |
| EP3980548A4 (en) * | 2019-04-30 | 2023-09-06 | The Trustees of The University of Pennsylvania | Compositions useful for treatment of pompe disease |
| WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| US20220259284A1 (en) | 2019-06-12 | 2022-08-18 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| CN112342247B (zh) * | 2020-11-10 | 2022-03-11 | 江苏科技大学 | 一种提高家蚕细胞表达外源蛋白分泌率的方法 |
| EP4255500A1 (en) | 2020-12-01 | 2023-10-11 | The Trustees of The University of Pennsylvania | Compositions and uses thereof for treatment of angelman syndrome |
| US20250034533A1 (en) | 2021-11-12 | 2025-01-30 | Amicus Therapeutics, Inc. | Compositions And Methods For Treating Mucopolysaccharidosis IIIA |
| WO2025264978A2 (en) | 2024-06-20 | 2025-12-26 | Amicus Therapeutics, Inc. | Recombinant alpha-galactosidase a proteins and gene therapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4892132B2 (ja) * | 1998-11-24 | 2012-03-07 | ブリストル−マイヤーズ スクイブ カンパニー | ７０ｋＤ熱ショック蛋白による化合物の細胞内標的輸送 |
| KR101348530B1 (ko) * | 2003-11-06 | 2014-02-14 | 다니스코 유에스 인크. | 프로테아제 저해자 및 그 변이체의 사상균 내에서의 발현 |
| DK2007885T3 (da) * | 2006-04-11 | 2010-11-08 | Csl Behring Gmbh | Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider |
-
2011
- 2011-11-22 DK DK11843849.8T patent/DK2643468T3/en active
- 2011-11-22 CN CN201180065369.5A patent/CN103328649B/zh active Active
- 2011-11-22 SI SI201131554T patent/SI2643468T1/sl unknown
- 2011-11-22 CA CA2818689A patent/CA2818689C/en active Active
- 2011-11-22 RS RS20180986A patent/RS57601B1/sr unknown
- 2011-11-22 HR HRP20181315TT patent/HRP20181315T1/hr unknown
- 2011-11-22 HU HUE11843849A patent/HUE039070T2/hu unknown
- 2011-11-22 ES ES11843849.8T patent/ES2687415T3/es active Active
- 2011-11-22 DK DK18181451.8T patent/DK3461905T3/da active
- 2011-11-22 PL PL11843849T patent/PL2643468T3/pl unknown
- 2011-11-22 EP EP11843849.8A patent/EP2643468B1/en active Active
- 2011-11-22 ES ES18181451T patent/ES2829199T3/es active Active
- 2011-11-22 PT PT11843849T patent/PT2643468T/pt unknown
- 2011-11-22 US US13/988,946 patent/US9279007B2/en active Active
- 2011-11-22 KR KR1020197015057A patent/KR20190060888A/ko not_active Ceased
- 2011-11-22 LT LTEP11843849.8T patent/LT2643468T/lt unknown
- 2011-11-22 SM SM20180466T patent/SMT201800466T1/it unknown
- 2011-11-22 KR KR1020137016110A patent/KR101984318B1/ko active Active
- 2011-11-22 EP EP18181451.8A patent/EP3461905B1/en active Active
- 2011-11-22 WO PCT/US2011/061862 patent/WO2012071422A2/en not_active Ceased
- 2011-11-22 BR BR112013012671-0A patent/BR112013012671B1/pt not_active IP Right Cessation
- 2011-11-22 JP JP2013541026A patent/JP2014503198A/ja not_active Withdrawn
-
2018
- 2018-09-12 CY CY181100941T patent/CY1121049T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9279007B2 (en) | 2016-03-08 |
| WO2012071422A3 (en) | 2012-08-02 |
| DK3461905T3 (da) | 2020-11-02 |
| CA2818689A1 (en) | 2012-05-31 |
| CA2818689C (en) | 2021-09-21 |
| RS57601B1 (sr) | 2018-11-30 |
| CN103328649A (zh) | 2013-09-25 |
| LT2643468T (lt) | 2018-09-10 |
| HUE039070T2 (hu) | 2018-12-28 |
| CN103328649B (zh) | 2016-06-22 |
| BR112013012671A2 (pt) | 2016-10-11 |
| CY1121049T1 (el) | 2019-12-11 |
| KR20130121878A (ko) | 2013-11-06 |
| JP2014503198A (ja) | 2014-02-13 |
| EP3461905A1 (en) | 2019-04-03 |
| HRP20181315T1 (hr) | 2018-10-19 |
| KR20190060888A (ko) | 2019-06-03 |
| EP3461905B1 (en) | 2020-08-05 |
| PT2643468T (pt) | 2018-10-11 |
| EP2643468A4 (en) | 2014-12-24 |
| DK2643468T3 (en) | 2018-09-24 |
| EP2643468A2 (en) | 2013-10-02 |
| SMT201800466T1 (it) | 2018-11-09 |
| WO2012071422A2 (en) | 2012-05-31 |
| SI2643468T1 (sl) | 2018-10-30 |
| PL2643468T3 (pl) | 2018-11-30 |
| US20140045216A1 (en) | 2014-02-13 |
| ES2829199T3 (es) | 2021-05-31 |
| EP2643468B1 (en) | 2018-07-04 |
| KR101984318B1 (ko) | 2019-05-31 |
| BR112013012671B1 (pt) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2687415T3 (es) | Nuevas secuencias señal para mejorar las expresiones de proteínas y la secreción de enzimas recombinantes y de otras proteínas | |
| Kermode | Mechanisms of intracellular protein transport and targeting in plant cells | |
| Lee et al. | Membrane topology of transmembrane proteins: determinants and experimental tools | |
| JPWO2000031284A1 (ja) | タンパク質発現ベクターとその使用 | |
| KR20210032972A (ko) | 전사인자를 사용하여 단백질 발현을 증가시키는 수단 및 방법 | |
| Ng et al. | Protein translocation across the endoplasmic reticulum | |
| KR20130020206A (ko) | 수용성 ｂｍｐ-2를 생산하는 재조합 대장균 및 이를 이용한 수용성 ｂｍｐ-2의 제조방법 | |
| CN103911383A (zh) | 适于家蚕丝腺表达的改造人酸性成纤维细胞生长因子基因及其表达系统和应用 | |
| US8067198B2 (en) | Protein expression system | |
| Hassan et al. | The trafficking of prosaposin (SGP‐1) and GM2AP to the lysosomes of TM4 sertoli cells is mediated by sortilin and monomeric adaptor proteins | |
| WO2012052170A1 (en) | Secretion of recombinant polypeptides in the extracellular medium of diatoms | |
| CN117120618A (zh) | 用于增加蛋白质分泌的信号肽 | |
| JP5177431B2 (ja) | ＴＲＡＣＰ５ｂの製造方法 | |
| HK40006980A (en) | Novel signal sequences to improve protein expression and secretion of recombinant enzymes and other proteins | |
| CN103374068A (zh) | 一种新的单克隆抗体的制备方法及用途 | |
| HK1189913A (en) | Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins | |
| HK1189913B (en) | Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins | |
| JP2007143497A (ja) | 魚類による蛋白質の製造方法 | |
| JP2007028966A (ja) | 外来酵素蛋白質の製造法、それに用いる遺伝子組換えカイコおよびその製造法 | |
| Lei Lei et al. | Prokaryotic expression of mouse Sox2 gene and preparation of its polyclonal antibody. | |
| WO2024193739A1 (en) | Method for producing proteins in host cells | |
| CN118696055A (zh) | 筛选用于在哺乳动物细胞中有效表达和分泌异源多肽的信号肽的方法 | |
| US20210388046A1 (en) | Chimeric signal peptides for protein production | |
| HK40102560A (zh) | 用於增加蛋白质分泌的信号肽 | |
| WO2008135259A2 (en) | Antibody molecule composition |